AHA Announces Last Minute Scientific Programming To Be Presented At Virtual Meeting


03 October 2021

2 minutes to read

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact customerservice@slakinc.com.

The American Heart Association Science Sessions will be a fully virtual event taking place November 13-15, 2021 and will feature seven last-minute science sessions over 3 days.

The latest delays include new data from the landmark EMPEROR-Preserved trial of empagliflozin (Jardiance, Boehringer Ingelheim / Eli Lilly) in patients with HF with preserved ejection fraction; the PREPARE-IT 2 trial on ethyl icosapent (Vascepa, Amarin) as an outpatient treatment with COVID-19; and the Fitbit Heart Study, which will provide data on the detection of atrial fibrillation in patients using the Fitbit wearable device.

heartbeat drawing
Source: Adobe Stock

The AHA has announced the following last-minute scientific programming for the annual meeting:

Late-Breaking Science 1: Valves, Veins, and New Perspectives in Cardiothoracic Surgery

  • Aortic valve replacement versus watchful waiting in severe asymptomatic aortic stenosis: the AVATAR trial
  • Evaluating the Benefits of Concomitant Tricuspid Repair During Mitral Valve Surgery
  • A randomized study of early coronary artery bypass graft surgery compared to standard surgery in patients with acute coronary syndromes treated with Ticagrelor (RAPID CABG)
  • Efficacy and safety of an external support device for saphenous vein coronary bypass grafts: the VEST trial

Late-Breaking Science 2: Hypertension: Local, Global and Pandemic Impacts

  • A remote hypertension and lipid program in 10,000 patients in a diverse healthcare network
  • Disruption of blood pressure monitoring with the COVID-19 pandemic: a study of 24 U.S. health systems in the PCORnet blood pressure monitoring lab (BP Track)
  • A cluster-randomized trial of a village doctor-led intervention on blood pressure control: China Rural Hypertension Control Project (CRHCP)

Late-breaking science 3: From prevention to intervention in atrial arrhythmias

  • The Coffee and Real-Time Atrial-Ventricular Ectopia (CRAVE) Trial
  • Dabigatran versus warfarin on cognitive outcomes of nonvalvular atrial fibrillation: results of the GIRAF trial
  • Left posterior pericardiotomy reduces postoperative atrial fibrillation after cardiac surgery (PALACS)
  • Results of adjuvant left atrial appendage ligation using LARIAT versus antral pulmonary vein isolation alone: ​​the AMAZE trial

Last Minute Science 4: Information Overload? Strive to improve care delivery through digital health and automated data

  • Risk assessment and its impact on clinical decision-making and heart failure outcomes: the REVeAL-HF trial
  • Detecting Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study
  • Testing for Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib)

Late-Breaking Science 5: Building on Treatment Foundations: Advances in Heart Failure Treatment

  • Heart Failure with 50% Preserved Ejection Fraction – EMPEROR-Preserved Clinical Trial Results
  • The Clinical Trial Impact of Canagliflozin on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF)
  • Efficacy and Safety of Empagliflozin in Hospitalized Patients with Heart Failure: Main Results from the EMPULSE Trial
  • Randomized trial of targeted transendocardial administration of mesenchymal precursor cells in high-risk chronic heart failure patients with reduced ejection fraction (DREAM-HF)

Last minute science 6: Fish oil, cocoa and cholesterol: recipes for CVD prevention?

  • Icosapent Ethyl versus placebo on an outpatient basis with Covid-19: the main results of PREPARE-IT 2
  • Key Findings from the Cocoa Supplements and Multivitamins (COSMOS) Study on Prevention of Cardiovascular Disease
  • Clinical Safety, Pharmacokinetics, and LDL Cholesterol Reducing Efficacy of MK-0616, an Oral PCSK9 Inhibitor

Breaking News 7: New Drugs and New Drug Indications in Cardiovascular Disease

  • Effects of Aspirin on Dementia and Cognitive Impairment in the ASCEND Trial
  • P2y12 inhibitors in non-critically ill hospitalized patients with Covid-19 (ACTIV-4A)
  • Effect of Bentracimab on Platelet Inhibition and Hemostasis in Ticagrelor Patients with Uncontrolled Bleeding or Requiring Urgent Surgery on REVERSE-IT
  • Milvexian for the prevention of venous thromboembolism after elective knee replacement surgery: the AXIOMATIC-TKR study


Previous Aryan Khan, son of Shah Rukh Khan, arrested during an anti-drug cruise raid; taken for medical examination [PHOTOS]
Next PNP chief in paris: avoid drugs

No Comment

Leave a reply

Your email address will not be published.